Skip to main content

Advertisement

Table 2 Univariate analyses of TGFBI methylation in non-small cell lung cancer patients

From: Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR

Variable Methylation status P-value
  Absent Present  
Age (mean ± SD) 57.5 ± 8.4 60.0 ± 8.2 0.3037
Sex    0.4900
   Male 26 (56.5%) 20 (43.5%)  
   Female 1 (25.0%) 3 (75.0%)  
Pathological stage    0.8766
   I 9 (50.0%) 9 (50.0%)  
   II 6 (50.0%) 6 (50.0%)  
   III 10 (62.5%) 6 (37.5%)  
   IV 2 (50.0%) 2 (50.0%)  
Differentiation    0.3890
   Well 1 (50.0%) 1 (50.0%)  
   Moderate 15 (48.4%) 16 (51.6%)  
   Poor 8 (57.1%) 6 (42.9%)  
   Unknown 3 (100.0%) 0 (0.0%)  
Tumor size (cm) (mean ± SD) 4.19 ± 2.34 4.62 ± 2.62 0.6543
Tumor status    0.2946
   T1 11 (61.1%) 7 (38.9%)  
   T2 12 (46.2%) 14 (53.8%)  
   T3 2 (66.7%) 1 (33.3%)  
   T4 1 (100.0%) 0 (0.0%)  
   Tx 2 (100.0%) 0 (0.0%)  
Metastatic status    0.6871
   Primary tumor 22 (61.1%) 14 (38.9%)  
   Lymph node metastasis 4 (40.0%) 6 (60.0%)  
   Distant metastasis 2 (50.0%) 2 (50.0%)  
Histology    0.6614
   Adenocarcinoma 14 (58.3%) 10 (41.7%)  
   Squamous cell carcinoma 12 (52.2%) 11 (47.8%)